OTC Markets OTCPK - Delayed Quote USD

Bristol-Myers Squibb Company PFD CONV 2 (BMYMP)

Compare
935.22
+3.67
+(0.39%)
As of January 13 at 1:02:47 PM EST. Market Open.
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for BMYMP

Recent News: BMYMP

View More
ArsenalBio and Bristol Myers Squibb Achieve Milestone for AB-4000 Series as Part of Ongoing Multi-Program Collaboration to Advance Next-Generation T Cell Therapies for Solid Tumors

ArsenalBio and Bristol Myers Squibb Achieve Milestone for AB-4000 Series as Part of Ongoing Multi-Program Collaboration to Advance Next-Generation T Cell Therapies for Solid Tumors
GlobeNewswire yesterday
AI, vaccine distrust, & the future of healthcare: Novartis CEO

AI, vaccine distrust, & the future of healthcare: Novartis CEO
Yahoo Finance Video 4 days ago
Bristol-Myers Squibb (NYSE:BMY) Has A Pretty Healthy Balance Sheet

Bristol-Myers Squibb (NYSE:BMY) Has A Pretty Healthy Balance Sheet
Simply Wall St. 7 days ago
Bristol Myers Squibb to Present at J.P. Morgan’s 43rd Annual Healthcare Conference

Bristol Myers Squibb to Present at J.P. Morgan’s 43rd Annual Healthcare Conference
Business Wire 11 days ago
Bristol-Myers Squibb's (NYSE:BMY) investors will be pleased with their 2.4% return over the last five years

Bristol-Myers Squibb's (NYSE:BMY) investors will be pleased with their 2.4% return over the last five years
Simply Wall St. 12 days ago
Bristol-Myers Squibb (NYSE:BMY) Is Paying Out A Larger Dividend Than Last Year

Bristol-Myers Squibb (NYSE:BMY) Is Paying Out A Larger Dividend Than Last Year
Simply Wall St. 16 days ago
U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo® (nivolumab) Indications1,2

U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo® (nivolumab) Indications1,2
Business Wire 17 days ago
Bristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic Arthritis

Bristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic Arthritis
Business Wire 22 days ago
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer

Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer
Business Wire 22 days ago
Bristol-Myers Squibb Company (NYSE:BMY) is a favorite amongst institutional investors who own 78%

Bristol-Myers Squibb Company (NYSE:BMY) is a favorite amongst institutional investors who own 78%
Simply Wall St. 23 days ago
Bristol Myers Squibb Stock Earns 83 RS Rating

Bristol Myers Squibb Stock Earns 83 RS Rating
Investor's Business Daily 25 days ago
View More

Related Tickers

MRK Merck & Co., Inc.
99.14
-1.82%
 
ABBV AbbVie Inc.
174.60
-1.21%
 
PFE Pfizer Inc.
26.51
-1.06%
 
NVO Novo Nordisk A/S
80.36
-5.03%
 
JNJ Johnson & Johnson
142.96
-1.04%
 
LLY Eli Lilly and Company
740.00
-7.21%